A mitochondrial-targeting peptide and administration of isolated mitochondria are different interventions. This experiment studied them separately and together. Primary study
What the study tested
Male rats were allocated to five groups, with eight animals per group, in a cardiac ischemia–reperfusion experiment. The combination of SS-31 and donor liver mitochondria produced more favorable short-term cardiac-function and injury-related findings than either intervention alone. Follow-up included a 72-hour assessment. Separate cell experiments examined additional mechanistic responses. Primary report
Our appraisal: preserve the components of the intervention
Reporting the combination result as the effect of SS-31 alone would assign benefit to the wrong intervention. A clear summary names the separate components and identifies the exact comparison that produced the finding.
Likewise, superiority of a combination to each component is not automatically evidence of synergy. Synergy concerns departure from an expected joint effect under a defined model. It requires more than ranking the group averages or finding two significant pairwise comparisons.
The follow-up interval shapes the conclusion. A cardiac-function measurement after several days can be informative about early injury, but it cannot establish durable remodeling, long-term survival, or sustained exercise capacity. Any future clinical discussion needs those outcomes rather than assuming persistence.
Cell experiments add another layer but not an automatic causal bridge. Changes in regulatory proteins or cellular ATP do not prove that the same pathway accounts for the whole-animal result. Differences in injury exposure, cell type, and intervention conditions should be kept explicit.
For evidence synthesis, this study should be indexed as a combination experiment, not pooled indiscriminately with peptide-only trials. Before publication, review should inspect allocation, blinding, handling of multiple comparisons, and the rationale for the interaction language. The report does not establish a treatment for human myocardial infarction or validate commercial SS-31 products.
Frequently asked questions
Was SS-31 the only active intervention?
No; isolated donor mitochondria were also studied.
Were there separate component groups?
Yes.
Was the combined response more favorable?
The authors reported that pattern for several outcomes.
Does that automatically prove synergy?
No.
Was long-term human survival studied?
No.
Can cell signaling identify the sole in-vivo mechanism?
Not by itself.
How should this be classified in an evidence review?
As a preclinical combination study with distinct component comparisons.